Osaic Holdings
TGTX icon

Osaic Holdings’s TG Therapeutics TGTX Stock Holding History

Osaic Holdings’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5M Buy
372,588
+100,980
+37% +$4.13M 0.02% 656
2026
Q1 		$9.02M Sell
271,608
-14,147
-5% -$422K 0.01% 983
2025
Q4 		$8.52M Buy
285,755
+159,162
+126% +$5.2M 0.01% 1039
2025
Q3 		$3.8M Buy
126,593
+13,248
+12% +$436K 0.01% 1690
2025
Q2 		$4.08M Sell
113,345
-39,445
-26% -$1.47M 0.01% 1380
2025
Q1 		$6.02M Buy
152,790
+50,996
+50% +$1.72M 0.01% 956
2024
Q4 		$3.06M Buy
101,794
+34,559
+51% +$992K 0.01% 1341
2024
Q3 		$1.57M Sell
67,235
-8,352
-11% -$182K ﹤0.01% 1906
2024
Q2 		$1.34M Buy
75,587
+19,264
+34% +$307K ﹤0.01% 1951
2024
Q1 		$857K Sell
56,323
-43,022
-43% -$685K ﹤0.01% 2492
2023
Q4 		$1.7M Sell
99,345
-19,511
-16% -$227K ﹤0.01% 1991
2023
Q3 		$993K Buy
118,856
+42,373
+55% +$591K ﹤0.01% 2637
2023
Q2 		$1.9M Buy
76,483
+21,340
+39% +$551K ﹤0.01% 1919
2023
Q1 		$833K Buy
55,143
+18,696
+51% +$284K ﹤0.01% 2647
2022
Q4 		$430K Buy
36,447
+6,007
+20% +$43.6K ﹤0.01% 3167
2022
Q3 		$179K Sell
30,440
-2,663
-8% -$17.5K ﹤0.01% 3856
2022
Q2 		$142K Sell
33,103
-1,330
-4% -$8.3K ﹤0.01% 4110
2022
Q1 		$328K Buy
34,433
+11,406
+50% +$132K ﹤0.01% 3609
2021
Q4 		$441K Sell
23,027
-11,897
-34% -$309K ﹤0.01% 3184
2021
Q3 		$1.16M Buy
34,924
+5,899
+20% +$183K ﹤0.01% 2210
2021
Q2 		$1.13M Buy
29,025
+4,404
+18% +$173K ﹤0.01% 2251
2021
Q1 		$1.19M Buy
24,621
+820
+3% +$39.4K ﹤0.01% 2075
2020
Q4 		$1.24M Sell
23,801
-10,786
-31% -$364K ﹤0.01% 1844
2020
Q3 		$927K Buy
34,587
+11,356
+49% +$261K ﹤0.01% 1897
2020
Q2 		$454K Sell
23,231
-3,912
-14% -$63K ﹤0.01% 2423
2020
Q1 		$268K Buy
+27,143
New +$343K ﹤0.01% 2624

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Osaic Holdings's TGTX Position: Q2 2026 in Review

Osaic Holdings increased its TG Therapeutics (TGTX) stake by 37% in Q2 2026, buying an estimated $4.13M and bringing the position to 372,588 shares worth $20.5M. The position accounts for 0.02% of the portfolio, ranked #656.

Osaic Holdings first reported a position in TGTX in Q1 2020 and has held it in 26 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Osaic Holdings held 372,588 shares of TG Therapeutics worth $20.5M as of Q2 2026.
  • Osaic Holdings bought 100,980 TG Therapeutics shares in Q2 2026, an estimated $4.13M.
  • TG Therapeutics made up 0.02% of Osaic Holdings's portfolio in Q2 2026, its #656 holding.
  • Osaic Holdings first reported a position in TG Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.